SA515361127B1 - مثبطات كبت مناعي يسـاهم في حدوثه التمثيل الغذائي للتريبتوفان - Google Patents

مثبطات كبت مناعي يسـاهم في حدوثه التمثيل الغذائي للتريبتوفان

Info

Publication number
SA515361127B1
SA515361127B1 SA515361127A SA515361127A SA515361127B1 SA 515361127 B1 SA515361127 B1 SA 515361127B1 SA 515361127 A SA515361127 A SA 515361127A SA 515361127 A SA515361127 A SA 515361127A SA 515361127 B1 SA515361127 B1 SA 515361127B1
Authority
SA
Saudi Arabia
Prior art keywords
tryptophan
treating
inhibitors
metabolization
immunosuppression
Prior art date
Application number
SA515361127A
Other languages
English (en)
Inventor
والدو جيسي
كومار سانجيف
جايبوري فيروز
ماوتينو ماريو
Original Assignee
نيولينك جينتكس كوربوريشن
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50686105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SA515361127(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by نيولينك جينتكس كوربوريشن filed Critical نيولينك جينتكس كوربوريشن
Publication of SA515361127B1 publication Critical patent/SA515361127B1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

يتعلق الاختراع الحالي بمثبطات IDO وTDO وتركيبات صيدلانية منها، مفيدة لتنظيم نشاط إندول أمين indoleamine 2، 3-داي أكسيجيناز dioxygenase وتريبتوفان tryptophan 2، 3داي أكسيجيناز dioxygenase ؛ علاج الكبت المناعي treating immunosuppression ؛ علاج حالات مرضية تستفيد من تثبيط تحلل التريبتوفان tryptophan degradation ؛ تحسين فاعلية علاج مضاد للسرطان anti-cancer يشتمل على إعطاء عقار مضاد للسرطان؛ علاج كبت مناعي immunosupression لورم مصاحب للسرطان ؛ وعلاج كبت مناعي مصاحب لمرض معدي infectious disease . شكل 1.
SA515361127A 2013-03-14 2015-09-14 مثبطات كبت مناعي يسـاهم في حدوثه التمثيل الغذائي للتريبتوفان SA515361127B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784089P 2013-03-14 2013-03-14
PCT/US2014/022680 WO2014159248A1 (en) 2013-03-14 2014-03-10 Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization

Publications (1)

Publication Number Publication Date
SA515361127B1 true SA515361127B1 (ar) 2017-10-19

Family

ID=50686105

Family Applications (1)

Application Number Title Priority Date Filing Date
SA515361127A SA515361127B1 (ar) 2013-03-14 2015-09-14 مثبطات كبت مناعي يسـاهم في حدوثه التمثيل الغذائي للتريبتوفان

Country Status (22)

Country Link
US (2) US9617272B2 (ar)
EP (2) EP3366678A1 (ar)
JP (2) JP6093903B2 (ar)
KR (1) KR20150126623A (ar)
CN (1) CN105189466A (ar)
AU (2) AU2014241079C1 (ar)
BR (1) BR112015022588A2 (ar)
CA (1) CA2902174A1 (ar)
CL (2) CL2015002649A1 (ar)
CR (1) CR20150485A (ar)
HK (1) HK1213259A1 (ar)
IL (1) IL241027A0 (ar)
MA (1) MA38493B1 (ar)
MX (1) MX361375B (ar)
PE (1) PE20151593A1 (ar)
PH (1) PH12015501866A1 (ar)
RU (1) RU2667509C2 (ar)
SA (1) SA515361127B1 (ar)
SG (2) SG10201707545XA (ar)
UA (1) UA118103C2 (ar)
WO (1) WO2014159248A1 (ar)
ZA (1) ZA201607948B (ar)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2694640T3 (ar) 2011-04-15 2018-03-17
JO3509B1 (ar) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
US10053463B2 (en) 2013-03-14 2018-08-21 Janssen Pharmaceutica Nv Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
AP2015008601A0 (en) 2013-03-14 2015-07-31 Boehringer Ingelheim Int Substituted 2-aza-bicyclo[2.2.1] heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C
JP6294953B2 (ja) 2013-03-14 2018-03-14 ヤンセン ファーマシューティカ エヌ.ベー. P2x7調節物質
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 P2x7調節劑
CN103570727B (zh) 2013-11-12 2015-08-19 复旦大学 一种n-苄基色胺酮衍生物及其制备方法和应用
CN107074859B (zh) 2014-09-05 2021-08-06 默克专利有限公司 用于治疗癌症的作为吲哚胺-2,3-双加氧酶(ido)拮抗剂的环己基乙基取代的二氮杂-和三氮杂-三环化合物
JP6592510B2 (ja) 2014-09-12 2019-10-16 ヤンセン ファーマシューティカ エヌ.ベー. P2x7調節因子
UA118610C2 (uk) 2014-09-12 2019-02-11 Бьорінгер Інгельхайм Інтернаціональ Гмбх Спіроциклічні інгібітори катепсину c
GB201417369D0 (en) * 2014-10-01 2014-11-12 Redx Pharma Ltd Compounds
US20160145344A1 (en) * 2014-10-20 2016-05-26 University Of Southern California Murine and human innate lymphoid cells and lung inflammation
AU2015341913B2 (en) * 2014-11-03 2020-07-16 Iomet Pharma Ltd Pharmaceutical compound
WO2016100851A1 (en) 2014-12-18 2016-06-23 Lankenau Institute For Medical Research Methods and compositions for the treatment of retinopathy and other ocular diseases
CN105884828A (zh) * 2015-02-16 2016-08-24 上海迪诺医药科技有限公司 多环化合物、其药物组合物及应用
CN107531693B (zh) * 2015-04-10 2021-07-06 百济神州有限公司 作为吲哚胺、色氨酸二加氧酶抑制剂的5或8-取代的咪唑并[1,5-a]吡啶
WO2016165613A1 (en) 2015-04-12 2016-10-20 Hangzhou Innogate Pharma Co., Ltd. Heterocycles useful as ido and tdo inhibitors
WO2016186967A1 (en) * 2015-05-15 2016-11-24 Gilead Sciences, Inc. Benzimidazole and imadazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase
GB2548542A (en) * 2015-06-16 2017-09-27 Redx Pharma Plc Compounds
CN105037371A (zh) * 2015-06-30 2015-11-11 西华大学 一种氘代的吲哚胺-2,3-双加氧酶抑制剂
CR20180023A (es) 2015-07-24 2018-03-20 Newlink Genetics Corp Sales y profármacos de 1-metil-d-triptofano
WO2017107979A1 (en) 2015-12-24 2017-06-29 Genentech, Inc. Tdo2 inhibitors
CN107056785B (zh) * 2016-01-02 2021-06-22 杭州英创医药科技有限公司 作为ido和tdo抑制剂的杂环化合物
SG11201806480UA (en) 2016-02-02 2018-08-30 Emcure Pharmaceuticals Ltd Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
CA3015012A1 (en) * 2016-02-19 2017-08-24 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tricyclic compound serving as immunomodulator
WO2017140272A1 (zh) * 2016-02-19 2017-08-24 正大天晴药业集团股份有限公司 作为免疫调节剂的三并环化合物
WO2017149469A1 (en) 2016-03-03 2017-09-08 Emcure Pharmaceuticals Limited Heterocyclic compounds useful as ido and/or tdo modulators
MX2018013164A (es) 2016-04-29 2019-06-24 Iomet Pharma Ltd Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.
WO2017198159A1 (zh) * 2016-05-16 2017-11-23 鲁南制药集团股份有限公司 含桥环的咪唑衍生物
CN107383012B (zh) * 2016-05-16 2021-09-28 鲁南制药集团股份有限公司 含二环的咪唑醇衍生物
CN107663159A (zh) * 2016-07-29 2018-02-06 上海迪诺医药科技有限公司 多环化合物、其药物组合物及应用
US11607426B2 (en) 2016-09-19 2023-03-21 University Of South Florida Method of targeting oncolytic viruses to tumors
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ido及tdo調節之化合物及方法以及其適應症
WO2018054365A1 (en) * 2016-09-24 2018-03-29 Beigene, Ltd. NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES
ES2939646T3 (es) 2016-10-13 2023-04-25 Juno Therapeutics Inc Métodos y composiciones de inmunoterapia que comprenden moduladores de la vía metabólica del triptófano
TW201815793A (zh) * 2016-10-21 2018-05-01 江蘇恆瑞醫藥股份有限公司 一種咪唑並異吲哚類衍生物的遊離鹼的結晶形式及其製備方法
CN108203438B (zh) * 2016-12-20 2021-09-28 深圳微芯生物科技股份有限公司 具有吲哚胺2,3-双加氧酶抑制活性的稠合咪唑化合物
SI3559009T1 (sl) 2016-12-22 2021-08-31 Calithera Biosciences, Inc. Sestavki in postopki za zaviranje arginazne dejavnosti
CA3047002A1 (en) 2017-01-17 2018-07-26 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
EP3645533A1 (en) 2017-06-28 2020-05-06 Genentech, Inc. Tdo2 and ido1 inhibitors
WO2019006047A1 (en) 2017-06-28 2019-01-03 Genentech, Inc. INHIBITORS OF TDO2 AND IDO1
CN109384791B (zh) * 2017-08-09 2020-09-11 江苏恒瑞医药股份有限公司 一种咪唑并异吲哚类衍生物游离碱的晶型及其制备方法
JP6931067B2 (ja) * 2017-09-15 2021-09-01 大鵬薬品工業株式会社 Idoの発現が関与する疾患の予防及び/又は治療剤
JP7306634B2 (ja) * 2017-10-19 2023-07-11 一般社団法人ファルマバレープロジェクト支援機構 Ido/tdo阻害剤
CN111386114A (zh) 2017-11-25 2020-07-07 百济神州有限公司 作为吲哚胺2,3-双加氧酶的选择性抑制剂的新颖苯并咪唑
CN111587116A (zh) 2018-01-05 2020-08-25 迪克纳制药公司 降低β-连环蛋白和IDO表达以加强免疫疗法
CN112119072A (zh) 2018-03-20 2020-12-22 普莱希科公司 用于ido和tdo调节的化合物和方法,以及其适应症
WO2020018670A1 (en) 2018-07-17 2020-01-23 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
TW202035409A (zh) 2018-09-28 2020-10-01 比利時商健生藥品公司 單醯基甘油脂肪酶調節劑
MA53721A (fr) 2018-09-28 2021-09-15 Janssen Pharmaceutica Nv Modulateurs de la monoacylglycérol lipase
CN114555596A (zh) 2019-09-30 2022-05-27 詹森药业有限公司 放射性标记的mgl pet配体
BR112022019077A2 (pt) 2020-03-26 2022-12-27 Janssen Pharmaceutica Nv Moduladores da monoacilglicerol lipase
US11839659B2 (en) 2020-07-02 2023-12-12 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
JP2024510949A (ja) 2021-03-05 2024-03-12 ウニヴェルシタット・バーゼル Ebv関連疾患又は状態の治療用組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH516573A (de) * 1967-08-15 1971-12-15 Sandoz Ag Verfahren zur Herstellung von 5-Hydroxy-5-phenyl-2,3-dihydro-5H-imidazo(2,1-a)isoindolen
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US6395876B1 (en) 1997-12-05 2002-05-28 Medical College Of Georgia Research Institute, Inc. High-affinity tryptophan transporter
WO2003087347A1 (en) 2002-04-12 2003-10-23 Medical College Of Georgia Research Institute, Inc. Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
AU2003234567A1 (en) * 2002-05-15 2003-12-02 Janssen Pharmaceutica N.V. N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors
EP2260846B1 (en) 2003-03-27 2018-11-28 Lankenau Institute for Medical Research Novel methods for the treatment of cancer
DE102007020493A1 (de) 2007-04-30 2008-11-06 Grünenthal GmbH Substituierte Amid-Derivate
CA2932121A1 (en) 2007-11-30 2009-06-11 Newlink Genetics Corporation Ido inhibitors
CN102083429B (zh) 2008-04-24 2014-05-28 新联基因公司 Ido抑制剂
US8541595B2 (en) * 2008-11-13 2013-09-24 Merch Sharp & Dohme Corp. Imidazoisoindole neuropeptide S receptor antagonists
US8722720B2 (en) 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
JP2012037986A (ja) 2010-08-04 2012-02-23 Canon Inc 画像形成装置及びその制御方法と画像形成システム
NO2694640T3 (ar) * 2011-04-15 2018-03-17

Also Published As

Publication number Publication date
RU2015143990A (ru) 2017-04-19
IL241027A0 (en) 2015-11-30
AU2014241079B2 (en) 2016-12-15
US9981973B2 (en) 2018-05-29
EP2976332A1 (en) 2016-01-27
CL2016001940A1 (es) 2017-03-10
JP6093903B2 (ja) 2017-03-08
EP2976332B1 (en) 2018-01-31
CA2902174A1 (en) 2014-10-02
KR20150126623A (ko) 2015-11-12
AU2014241079C1 (en) 2017-07-06
US20160060266A1 (en) 2016-03-03
PH12015501866A1 (en) 2015-12-07
US9617272B2 (en) 2017-04-11
MA38493B1 (fr) 2017-10-31
MA38493A1 (fr) 2017-02-28
AU2014241079B9 (en) 2017-04-06
BR112015022588A2 (pt) 2017-07-18
UA118103C2 (uk) 2018-11-26
RU2667509C2 (ru) 2018-09-21
HK1213259A1 (zh) 2016-06-30
JP2017052786A (ja) 2017-03-16
JP6352368B2 (ja) 2018-07-04
AU2014241079A1 (en) 2015-09-03
SG10201707545XA (en) 2017-10-30
WO2014159248A1 (en) 2014-10-02
EP3366678A1 (en) 2018-08-29
CR20150485A (es) 2015-11-26
PE20151593A1 (es) 2015-11-05
MX361375B (es) 2018-12-05
CN105189466A (zh) 2015-12-23
US20170260188A1 (en) 2017-09-14
AU2017201693A1 (en) 2017-03-30
SG11201507255QA (en) 2015-10-29
ZA201607948B (en) 2018-05-30
MX2015011385A (es) 2016-02-03
JP2016519056A (ja) 2016-06-30
CL2015002649A1 (es) 2016-07-29

Similar Documents

Publication Publication Date Title
SA515361127B1 (ar) مثبطات كبت مناعي يسـاهم في حدوثه التمثيل الغذائي للتريبتوفان
MX2013012021A (es) Derivados de imidazol fusionados utiles como inhibidores de indoleamina 2-3 dioxigenasa (ido).
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
PH12015502028A1 (en) Ido inhibitors
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
MX2016000295A (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
EA201790674A1 (ru) Индуцирующий цитотоксичность терапевтический агент
MX2016007351A (es) Terapia de combinacion para tratar cancer.
GEP20217247B (en) Indole derivatives for use in medicine
EA201991772A1 (ru) Способ лечения рака предстательной железы с использованием комбинации на основе модулятора андрогенного рецептора
EA201591599A1 (ru) Ингибиторы ido
NZ708382A (en) Cycloalkyl bis-thiadiazole inhibitors of glutaminase and their use as therapeutic agents
PH12016502354A1 (en) Pharmaceutical composition
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
JO3438B1 (ar) مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
NZ729643A (en) Combination therapy for treating cancer
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
EA201791933A1 (ru) Ингибирование активности olig2
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
PH12017502046A1 (en) Salts and prodrugs of 1-methyl-d-tryptophan
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.